Rybrevant Faspro
Active substance: AMIVANTAMAB, HYALURONIDASE (HUMAN RECOMBINANT)
INJECTION · AMIVANTAMAB 2240 mg/14mL, HYALURONIDASE (HUMAN RECOMBINANT) 28000 mg/14mL
United StatesActive
Marketing holder: Janssen Biotech, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 3
Composition
- AMIVANTAMAB · 2240 mg/14mL
- HYALURONIDASE (HUMAN RECOMBINANT) · 28000 mg/14mL
Products containing amivantamab in other countries
Showing products with this active substance, combinations included; the full composition is shown for each product.
| Country | Products |
|---|---|
| RU 1 |
|
| EU 1 |
|
Import and control
Control by country
- Russiaprescription only
Source: GRLS (Russian state register) · record 01a120c3-dbb9-770c-a8f2-c525bdfd6071;count=1 · valid from 2026-10-09 · verified 2026-10-09
- United Statesprescription only
Source: openFDA NDC · record 01a1208f-f65e-7be4-84d3-01dcb734e8b3;count=1 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 57894-514
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- SUBCUTANEOUS
Sources
- product · openFDA NDC · 57894-514 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 57894-514 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 57894-514 · Verified 2026-10-09 · open in source
- ingredients.1 · openFDA NDC · 57894-514 · Verified 2026-10-09 · open in source